Immunotherapy plus chemoradiotherapy for older adults with esophageal squamous cell carcinoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-center, open-label, retrospective review will analyze medical records of patients aged 70 or older with histologically confirmed esophageal squamous cell carcinoma who received concurrent chemoradiotherapy plus immunotherapy at a Chongqing hospital. Investigators will record tumor responses (ORR, DCR), survival outcomes (OS, PFS), duration of response, R0 resection rates, and treatment-related adverse events. Available tissue or blood samples will be examined for potential predictive biomarkers. The aim is to characterize safety and real-world effectiveness of the combination in an elderly population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Voluntary participation with written informed consent. Age ≥70 years, regardless of gender. Histologically or cytologically confirmed ESCC. Inoperable or refusal of surgery, with tolerance for anti-tumor treatment. ECOG performance status 0-2. Expected survival ≥6 months. No severe abnormalities in hematologic, cardiac, pulmonary, hepatic, or renal function, and no immunodeficiencies.

Exclusion Criteria:

* No severe abnormalities in hematologic, cardiac, pulmonary, hepatic, or renal function, and no immunodeficiencies.

Exclusion Criteria:

Distant organ metastasis (excluding supraclavicular lymph nodes). Previous esophageal fistula, perforation, or pre-treatment for malignancy. Prior thoracic radiotherapy. Active autoimmune diseases or history of autoimmune diseases. Previous or ongoing PD-1 inhibitor treatment or participation in other interventional clinical studies.

Allergy to large protein formulations or components of S-1 capsules. Uncontrolled cardiac conditions. Immunodeficiencies (e.g., HIV infection), active hepatitis B or C, or active tuberculosis.

Active infection or unexplained fever \>38.5°C within 2 weeks before screening. History of other malignancies within 5 years (except cured basal cell carcinoma of the skin or cervical carcinoma in situ).

Where it's running

• Affiliated Shangxia Hospital of Chongqing University
  Chongqing, Chongqing Municipality, China Recruiting

Study contacts

• Study coordinator: Han Zhang
• Email: 4081548@qq.com
• Phone: 86-15023366912

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CR-002 study in adults with advanced solid tumors

  This trial tests CR-002 as a single therapy to see if it is safe and tolerable in adults with locally advanced or metastatic solid tumors

  Recruiting at 3 sites Phase 1/2 Crescent Biopharma, Inc. · Austin, Texas and 2 other locations · NCT07909031

• Neoadjuvant CTLA-4 and PD-1 blockade with chemoradiotherapy for locally advanced ESCC

  This trial tests whether giving two immune checkpoint inhibitors before surgery, together with chemoradiotherapy, helps patients with resectable locally advanced esophageal squamous cell carcinoma.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07751055

• PD-1 inhibitors with local therapy at different timings in oligometastatic ESCC

  This study tests whether giving local radiotherapy at different times around PD-1 inhibitor therapy helps people with oligometastatic esophageal squamous cell carcinoma.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT07697859

• Adebrelimab plus chemotherapy before surgery for borderline-resectable esophageal squamous cell carcinoma

  This trial tests whether adding adebrelimab to chemotherapy given before surgery can shrink borderline-resectable ESCC enough to allow curative tumor removal.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07638436

• Adebrelimab with neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma

  This study tests whether giving adebrelimab with paclitaxel, carboplatin, and short-course radiotherapy before surgery helps ESCC patients.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07595770

• Starting chemo plus PD-1 immunotherapy before radiation versus giving chemo during radiation for unresectable locally advanced esophageal squamous cell carcinoma

  This trial sees if giving three cycles of chemotherapy with a PD-1 immunotherapy before radiation, followed by maintenance immunotherapy, works better than giving chemotherapy at the same time as radiation followed by the same maintenance for people with unresectable locally advanced esophageal squamous cell carcinoma.

  Recruiting Phase 2 Second Affiliated Hospital of Zunyi Medical University · Zunyi, Guizhou · NCT07559045

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.